An Open Label, Randomized, 2-Period, Crossover Study to Establish the Definitive Bioequivalence of Niacin and MK0524 of 2 Sources of MK0524A Tablets.
Phase of Trial: Phase I
Latest Information Update: 25 Jun 2015
At a glance
- Drugs Niacin/laropiprant (Primary)
- Indications Hyperlipidaemia
- Focus Pharmacokinetics
- Sponsors Merck & Co; Merck Sharp & Dohme
- 09 Dec 2009 Patient numbers amended from 160 to 188 as reported by ClinicalTrials.gov.
- 29 Jul 2009 New trial record